02/06/2026 | Press release | Distributed by Public on 02/06/2026 05:19
On 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva.
The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official partner, IFPMA remains fully committed to working with WHO, Member States, and all stakeholders to support a process that delivers sustainable and pragmatic solutions for reform.
We believe that three priorities are essential for lasting impact:
We look forward to engaging meaningfully on this process and to working together toward a healthier future for all.
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.